Codexis Inc. today announced the appointment of Brian Fenton to the position of Associate Director Business Development, North America.

Based strategically in the Northeast biopharmaceutical corridor, Mr. Fenton will be responsible for establishing new business relationships with industry leaders in the pharmaceutical and biotechnology sectors, as well as managing Codexis’ principal North American partnerships that include Eli Lilly and Pfizer.

Prior to joining Codexis, Mr. Fenton was a key member in the global technology licensing and new business development activities of Abbott Bioresearch Center (ABC) in Worcester, Mass., part of Abbott Laboratories. In this capacity, Mr. Fenton led the strategy, formation and execution of strategic partnering in the area of biologics contract manufacturing at ABC. He also co-chaired ABC’s Antibody Platform Strategy Team and was responsible for several successful research and commercial agreements including Abbott’s gene switching technology and other proprietary intellectual property.

Prior to joining ABC, Mr. Fenton held senior business and process development roles over an eight-year period with BASF Bioresearch Corporation, having begun his career at Biopure Corporation in Boston.

”We are delighted to welcome Brian to our business development team, as he brings with him a wealth of experience in the negotiation of both research and commercial business partnerships,” said Kevin Taylor, Vice President of Business Development at Codexis. “Brian will be responsible for the effective communication to the North American market of Codexis’ unique value proposition and proprietary technology platform, already proven in successful collaborations with partners including Eli Lilly, Pfizer, DSM and Novozymes.“

Mr. Fenton holds a MSc in Chemical Engineering from the University of Virginia and a MBA from Worcester Polytechnic Institute. He has been a co-chair in the Business Development Committee of the Massachusetts Biotech Council for the last five years.

About Codexis, Inc.

Codexis, Inc., a majority owned subsidiary of Maxygen, Inc., is a provider of biocatalysis and fermentation processes and products to the life science and allied trade industries. Codexis’ proprietary MolecularBreeding™ directed molecular evolution allows for the discovery and development of improved or novel processes for the efficient and cost-effective synthesis of valuable pharmaceuticals and chemical compounds utilizing proprietary biocatalysts and fermentation production strains. Codexis has entered into ten strategic alliances involving its MolecularBreedingÔ directed evolution platform, and has over 19 potential products and processes in development with partners and in its own R&D pipeline. In addition, Codexis has five processes now operating at commercial scale, each generating royalty payments. Codexis commenced operations as an independent company in October 2002. MolecularBreeding is a trademark of Maxygen, Inc. Codexis is a trademark of Codexis, Inc.

Contact:
Codexis, Inc.
Tassos Gianakakos
Sr. Vice President, Business Development
T. +1-650-298-5423
F. +1-650-298-5449
tassos.gianakakos@codexis.com